Psychosis: An Overlooked Manifestation of Parkinson’s Disease?

Activity Information

Release Date: August 25, 2016
Expiration Date: August 25, 2017
Estimated time to complete activity: 60 minutes

Supported Browsers

Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above

Medical Education Resources


Jointly provided by

This activity is supported by an educational grant from ACADIA Pharmaceuticals Inc.

Target Audience

This activity has been designed to meet the needs of neurologists, psychiatrists, nurse practitioners, and registered nurses who are involved in the management and treatment of patients with Parkinson’s disease.

Statement of Need/Program Overview

Psychotic symptoms are a frequent complication of Parkinson’s disease (PD) and may affect as many as 50% to 75% of patients with PD.1,2 Despite their prevalence, psychiatric manifestations have been an overlooked and poorly understood aspect of PD management. Worsening psychotic symptoms greatly complicate the care of a person with PD and can add to caregiver stress. There is evidence that physicians and other health care providers may be unaware of the prevalence and risk factors for PD-related psychosis and, therefore, may not evaluate and screen patients to detect early signs and symptoms.3 Health care providers need a greater awareness of the magnitude of this problem among patients with an existing diagnosis of PD or in those who later develop the disease. Even without psychotic symptoms, the treatment of PD involves a complex balance of managing motor symptoms while minimizing dyskinesia and other adverse effects of medications. Although PD-related psychosis is often treated with antipsychotic medications, these can worsen motor dysfunction.4 Recent research has explored newer medications for psychiatric manifestations of PD, but providers may be unfamiliar with their mechanisms. In this activity, expert faculty will discuss the risk factors, early detection, and differentiation of psychiatric symptoms in patients with PD, as well as strategies for current and emerging pharmacologic management approaches.

  1. Forsaa EB, Larsen JP, Wentzel-Larsen T, et al. A 12-year population based study of psychosis in Parkinson disease. Arch Neurol. 2010;67(8):996-1001.
  2. Williams DR, Warren JD, Lees AJ. Using the presence of visual hallucinations to differentiate Parkinson’s disease from atypical parkinsonism. J Neurol Neurosurg Psychiatry. 2008;79(6):652-655.
  3. Goetz CG, Stebbins GT, Ouyang B. Visual plus nonvisual hallucinations in Parkinson’s disease: development and evolution over 10 years. Mov Disord. 2011;26(12):2196-2200.
  4. Goldman JG, Holden S. Treatment of psychosis and dementia in Parkinson’s disease. Curr Treat Options Neurol. 2014;16(3):281.

Learning Goal/Purpose

The goal of this symposium is to educate health care providers on the latest information in the area of PD-related psychosis.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Review the epidemiology and risk factors for psychosis and psychiatric symptoms in PD
  • Differentiate the presentation of psychiatric symptoms in PD from that of motor symptoms
  • Identify specific screening tools to identify PD psychosis in its early stages
  • Enhance patient and caregiver evaluations to overcome barriers that may prevent them from disclosing psychiatric symptoms
  • Assess available treatment approaches for psychiatric manifestations of PD


Stuart H. Isaacson, MD
Parkinson’s Disease and Movement Disorders Center of Boca Raton
Associate Professor of Neurology
Florida International University
Herbert Wertheim College of Medicine
Boca Raton, Florida

Henry A. Nasrallah, MD
The Sydney W. Souers
Professor and Chair
Department of Neurology and Psychiatry
Saint Louis University School of Medicine
St. Louis, Missouri

Program Agenda

Psychosis: An Overlooked Manifestation of Parkinson’s Disease?

  • Parkinson’s Disease: Introduction
  • Parkinson’s Disease Psychosis
  • Phenomenology: Hallucinations and Delusions
  • NINDS-NIMH Diagnostic Criteria
  • Pathophysiology and Clinical Course
  • Management
  • Conclusions

Physician Credit

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and CMEology. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Medical Education Resources designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

This CE activity provides 1.0 contact hour of continuing nursing education.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 1.0 contact hour.

Disclosure of Conflicts of Interest

Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial entity

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Name of Faculty

Reported Financial Relationship

Stuart H. Issacson, MD

Consulting Fees, Grants/Research Support, and/or Speakers’ Bureau/Other Lectures on behalf of: Abbvie Inc., ACADIA Pharmaceuticals Inc., Adamas Pharmaceuticals, Inc., Addex Therapeutics, Allergan, Allon Therapeutics, Inc., Amarantus Bioscience Holdings, Inc., AstraZeneca, Auspex Pharmaceuticals, Biotie Therapies, Britannia Pharmaceuticals Ltd., Chelsea Therapeutics International, Ltd., Civitas Therapeutics, Inc., Cynapsus Therapeutics Inc., Eisai Co., Ltd., Eli Lilly and Company, EMD Serono, Inc., F. Hoffmann-La Roche Ltd., GE Healthcare, GlaxoSmithKline plc., H. Lundbeck A/S, Impax Pharmaceuticals, Ipsen Group, Kyowa Pharma Chemical Co., Medtronic, Merck & Co., Merz Pharma, Michael J. Fox Foundation, National Institutes of Health, Neurocrine Biosciences, Inc., Novartis AG, Orion Corporation, Parkinson Study Group, Pfizer Inc., Phytopharm, Purdue Pharma L.P., Santhera Pharmaceuticals, Shire, Teva Pharmaceutical Industries Ltd., UCB S.A., US WorldMeds, LLC., Vanda Pharmaceuticals, XenoPort, Inc.

Henry A. Nasrallah, MD

Consulting Fees, Grants/Research Support, and/or Speakers’ Bureau/Other Lectures on behalf of: ACADIA Pharmaceuticals Inc., Alkermes, Boehringer Ingelheim GmbH, FORUM Pharmaceuticals, Janssen Pharmaceuticals, Inc., Otsuka America Pharmaceutical, Inc., Sunovion Pharmaceuticals, Inc., Vanda Pharmaceuticals.

The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Name of Content Manager

Reported Financial Relationship

Rob Lowney (CMEology)

No financial relationships to disclose.

Dana Ravyn, PhD, MPH (CMEology)

No financial relationships to disclose.

Rachael Soranno (CMEology)

No financial relationships to disclose.

Julie Johnson, PharmD (MER)

No financial relationships to disclose.

Veronda Smith, FNP-BC (MER)

No financial relationships to disclose.

Method of Participation

There are no fees for participating in and receiving credit for this activity. During the period August 25, 2016 through August 25, 2017 participants must 1) read the educational objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest by recording the best answer to each question, and 4) complete the evaluation form.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.




The content and views presented in this educational activity are those of the faculty and do not necessarily reflect those of Medical Education Resources, CMEology, and/or ACADIA Pharmaceuticals Inc. The faculty have disclosed if there is any discussion in their presentations of published and/or investigational uses of agents that are not indicated by the FDA. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Fee Information

There is no fee for this educational activity.

MER Privacy Policy

Medical Education Resources maintains high standards for the protection of privacy over the Internet. The purpose of this statement is to explain what information we obtain, how it is used, and how visitors can restrict its use or disclosure.

The only information MER obtains is information supplied voluntarily by the visitor.

We do not sell or disclose individually identifiable information obtained online, unless it is required by law or if disclosure is necessary to protect the safety of customers, employees, or property.

We use the information to grade your posttest and to send you a certificate of completion of the activity. If we use a third-party company to grade your posttest and issue certificates of completion, we will give information to that company for that purpose only.

For each activity you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.

We may use the information to invite you to participate in other activities we offer.

Medical Education Resources is committed to safeguarding customer privacy, and we require our employees to protect the privacy of information about our customers. If you wish to delete your information from our files or discuss our privacy policy, please contact us at 303-798-9682.

Contact Information for Technical Questions

Please technical questions or concerns to Global Academy for Medical Education at 973-290-8253 or email

Copyright Statement

Copyright © 2016 by Global Academy for Medical Education, LLC, and its Licensors. All rights reserved. No part of this activity may be reproduced or transmitted in any form, by any means, without prior written permission of the Publisher. Global Academy for Medical Education, LLC, will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this activity, including any claims related to the products, drugs, or services mentioned herein.

click me